Shenzhen Reborngene Therapeutics

Reborngene Therapeutics is a clinical-stage biotechnology company based in Shenzhen, China, specializing in the development of recombinant adeno-associated virus (rAAV) gene therapies. The company's proprietary R-AAV platform enables the design of optimized viral vectors for treating both rare genetic disorders and high-incidence diseases. Its lead candidate, RB001, is an AAV-based gene therapy currently in Phase 1/2 clinical trials for Phelan-McDermid Syndrome, aiming to restore SHANK3 protein expression in the central nervous system. Reborngene is also advancing a pipeline of ophthalmic gene therapies targeting conditions such as wet age-related macular degeneration and diabetic macular edema.